[go: up one dir, main page]

WO2003088811A3 - Gelsolin as a prognostic marker of artherosclerotic diseases - Google Patents

Gelsolin as a prognostic marker of artherosclerotic diseases Download PDF

Info

Publication number
WO2003088811A3
WO2003088811A3 PCT/US2003/011722 US0311722W WO03088811A3 WO 2003088811 A3 WO2003088811 A3 WO 2003088811A3 US 0311722 W US0311722 W US 0311722W WO 03088811 A3 WO03088811 A3 WO 03088811A3
Authority
WO
WIPO (PCT)
Prior art keywords
gelsolin
subjects
risk
invention involves
diagnostic test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/011722
Other languages
French (fr)
Other versions
WO2003088811A2 (en
Inventor
Thomas P Stossel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Priority to AU2003226401A priority Critical patent/AU2003226401A1/en
Publication of WO2003088811A2 publication Critical patent/WO2003088811A2/en
Publication of WO2003088811A3 publication Critical patent/WO2003088811A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention involves the using blood gelsolin levels as a diagnostic test to determine the risk of artherosclerotic diseases such as myocardial infarction, stroke, and peripheral ischemic cardiovascular disease, particularly among subjects with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which subjects at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders.
PCT/US2003/011722 2002-04-16 2003-04-16 Gelsolin as a prognostic marker of artherosclerotic diseases Ceased WO2003088811A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003226401A AU2003226401A1 (en) 2002-04-16 2003-04-16 Gelsolin as a prognostic marker of artherosclerotic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37304302P 2002-04-16 2002-04-16
US60/373,043 2002-04-16

Publications (2)

Publication Number Publication Date
WO2003088811A2 WO2003088811A2 (en) 2003-10-30
WO2003088811A3 true WO2003088811A3 (en) 2004-02-26

Family

ID=29250950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/011722 Ceased WO2003088811A2 (en) 2002-04-16 2003-04-16 Gelsolin as a prognostic marker of artherosclerotic diseases

Country Status (2)

Country Link
AU (1) AU2003226401A1 (en)
WO (1) WO2003088811A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
PT1755661E (en) 2004-05-12 2014-06-03 Brigham & Womens Hospital Gelsolin for use in treating infections
CA2567223A1 (en) 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
CN107085113B (en) 2006-03-15 2020-07-17 布赖汉姆妇女医院有限公司 Use of gelsolin for diagnosis and treatment of inflammatory diseases
WO2007106577A2 (en) 2006-03-15 2007-09-20 The Brigham And Women's Hospital, Inc. Gelsolin in the treatment and diagnosis of neurological disease
ES2634263T3 (en) 2008-01-25 2017-09-27 The General Hospital Corporation Therapeutic diagnostic uses of gelsolin in renal failure
AU2011319319B2 (en) * 2010-10-20 2015-07-30 Eisai R&D Management Co., Ltd. Biomarker for Alzheimer's disease or mild cognitive impairment
EP2725360A1 (en) * 2012-10-24 2014-04-30 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Biomarkers for the prognosis of ischemic stroke
CN103242304A (en) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 Synthetic method of anti-inflammatory drug tenidap sodium
CN107300589A (en) * 2017-04-18 2017-10-27 广州仁恒医药科技股份有限公司 A kind of chromatographic purity assay method of Difluprednate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260224A (en) * 1990-04-11 1993-11-09 Brigham And Women's Hospital Therapeutic uses of actin-binding compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260224A (en) * 1990-04-11 1993-11-09 Brigham And Women's Hospital Therapeutic uses of actin-binding compounds

Also Published As

Publication number Publication date
WO2003088811A2 (en) 2003-10-30
AU2003226401A1 (en) 2003-11-03
AU2003226401A8 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
WO2003040691A3 (en) Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
Eggermont et al. Lower-extremity function in cognitively healthy aging, mild cognitive impairment, and Alzheimer's disease
von Haehling et al. Frailty and heart disease
WO2004103150A3 (en) Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin
Hirata et al. Endothelial function and cardiovascular events in chronic kidney disease
Grabowski et al. Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty
WO2007006858A3 (en) Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
ATE545032T1 (en) DIAGNOSIS OF CARDIOVASCULAR DISEASE
WO2010041046A8 (en) Granin proteins as markers of heart disease
BR0301719A (en) Process for diagnosing myocardial infarction and / or risk stratification of acute coronary syndrome, set of reagents to make this diagnosis and use it
WO2005000091A3 (en) Method and apparatus for detecting ischemia
WO2003088811A3 (en) Gelsolin as a prognostic marker of artherosclerotic diseases
Westhoff et al. The cardiovascular effects of upper-limb aerobic exercise in hypertensive patients
WO2005029066A3 (en) Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof
Löffler et al. Effect of renal function on prognosis in chronic heart failure
ATE375517T1 (en) DIAGNOSIS OF ACUTE MYOCARDIAL ISCHEMIC DISEASES THROUGH A COMBINATION OF MARKERS
Wright et al. Natriuretic peptides as a prognostic marker and therapeutic target in heart failure
Melin et al. Effects of enhanced external counterpulsation on skeletal muscle gene expression in patients with severe heart failure
WO2004107958A3 (en) Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Saleh et al. The association between depressive symptoms and N-terminal pro–B-type natriuretic peptide with functional status in patients with heart failure
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
Felmeden et al. Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: a substudy of the Anglo‐Scandinavian Cardiac Outcomes Trial (ASCOT)
de Wytt et al. Polyneuropathy in Australian outpatients with type II diabetes mellitus
Iqbal et al. Study on ST-segment elevation acute myocardial infarction (STEMI) in diabetic and non-diabetic patients
WO2021020920A3 (en) Kit for predicting or diagnosing nonalcoholic fatty liver disease, and method for diagnosing nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP